07/10/2026 US FDA grants two breakthrough therapy designations to AbbVie’s c-Met ADC Temab-A in CRC and NSCLC US FDA approves tucatinib-based maintenance regimen for HER2-positive Breast Cancer US FDA grants two breakthrough therapy designations to AbbVie’s c-Met ADC Temab-A in CRC and NSCLC (Ref) AbbVie announced that the US FDA has granted two Breakthrough Therapy Designations (BTDs) to c-Met-targeted antibody-drug conjugate (ADC), telisotuzumab adizutecan (Temab-A/ABBV-400

01/09/2026 Enhertu + pertuzumab secures EU approval as first-line treatment for HER2-positive breast cancer Enhertu + pertuzumab secures EU approval as first-line treatment for HER2-positive breast cancer (Ref) AstraZeneca & Daiichi Sankyo announced that Enhertu (trastuzumab deruxtecan; HER2-directed ADC) in combination with pertuzumab (HER2 dimerization-blocking monoclonal antibody) was approved in the European Union (EU) for the first-line treatment of adult patients with u